Journal article

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

MM Eatock, NC Tebbutt, CL Bampton, AH Strickland, M Valladares-Ayerbes, A Swieboda-Sadlej, E Van Cutsem, N Nanayakkara, Y-N Sun, ZD Zhong, MB Bass, AH Adewoye, G Bodoky

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2013

Abstract

BACKGROUND: We evaluated AMG 386, an investigational peptibody that neutralizes the interaction between angiopoietins-1 and -2 and the Tie2 receptor, combined with cisplatin/capecitabine (CX) as first-line treatment for metastatic gastro-oesophageal cancer. PATIENTS AND METHODS: Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P.O. BID for 14 days Q3W) plus intravenous AMG 386 10 mg/kg QW (Arm A) or 3 mg/kg QW (Arm B), or placebo QW (Arm C). The primary end point was estimated progression-free survival (PFS). RESULTS: A total of 171 patients were enrolled. Me..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

This work was funded by Amgen Inc.The authors have declared the following conflicts of interest: NCT has conducted research sponsored by Amgen Inc.; MV-A has received research funding from Roche and Amgen Inc. and has acted as a speaker and consultant for Amgen Inc., Merck-Serono, and Roche; NN is an employee of Quintiles and works as a contractor for Amgen Inc.; Y-NS, MBB, ZDZ, and AHA are employees of and shareholders in Amgen Inc.; MME, CLB, AS, AS-S, EVC, and GB have declared no conflicts of interest.